"In over 60% of patients with brain tumours, the disease is incurable, with the average life expectancy being less that one year despite the best available treatments."
The brain tumour research group investigates the basic molecular and cellular events that lead to the development of brain cancer to identify potential novel targets for biological therapies.
The RMH Melbourne Brain Centre research unit's clinical and translational research programs involve: Oncology, Trauma, Neurophysiology of Vision and Cerebrovascular Disease, particularly Subarachnoid Hemorrhage.
These are undertaken in collaboration with various departments of the University of Melbourne, RMH, VCCC, and international groups including Harvard University, The University of Auckland and The Hebrew University in Jerusalem.
The brain tumour group publishes 15-20 papers each year, and delivers educational presentations to numerous bodies and groups.